Učitavanje...
In Vivo Instability of (177)Lu-DOTATATE During Peptide Receptor Radionuclide Therapy
Peptide receptor radiotherapy using (177)Lu-labeled somatostatin ligand analogs is a well-established treatment for neuroendocrine tumors, with (177)Lu-DOTATATE having acquired marketing authorization in Europe and the United States. The investigation of the pharmacokinetics of these radiopharmaceut...
Spremljeno u:
| Izdano u: | J Nucl Med |
|---|---|
| Glavni autori: | , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Society of Nuclear Medicine
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7456166/ https://ncbi.nlm.nih.gov/pubmed/32005767 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.119.237818 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|